The beneficial effects of lipid-lowering therapy with xuezhikang on cardiac events and total mortality in coronary heart disease patients with or without hypertension: a random, double-blinded, placebo controlled clinical trial / 中华心血管病杂志
Chinese Journal of Cardiology
;
(12): 890-894, 2006.
Article
in Chinese
| WPRIM
| ID: wpr-238496
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in coronary heart disease (CHD) patients with or without hypertension.</p><p><b>METHODS</b>In this random, double-blinded, placebo controlled clinical trial, 2704 patients with hypertension and 2166 patients without hypertension were enrolled and capsule Xuezhikang 0.6 g Bid or placebo on the top of conventional therapy without other lipid-lowering drugs. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and total mortality.</p><p><b>RESULTS</b>Compared to placebo group, the incidence of cardiac events was reduced by 44.0% (P<0.0001) and 47.4% (P<0.0001) respectively in CHD patients with or without hypertension, and the total mortality was lowered by 35.8% (P=0.0012) and 28.6% (P=0.0737) respectively in CHD patients with or without hypertension. There was no significant difference in side effects between study groups.</p><p><b>CONCLUSION</b>Xuezhikang can reduce the cardiac events and mortality in CHD patients with or without hypertension.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood
/
Drugs, Chinese Herbal
/
Double-Blind Method
/
Survival Rate
/
Mortality
/
Coronary Disease
/
Therapeutic Uses
/
Drug Therapy
/
Hypertension
/
Lipids
Type of study:
Controlled clinical trial
/
Prognostic study
Limits:
Adolescent
/
Adult
/
Aged
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Cardiology
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS